---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000014"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:53:19.732239+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aldeyra advances RASP modulator pipeline; multiple IND submissions and trial initiations planned for 2024

## Summary
- Positive biomarker results from ADX-629 in Sjögren-Larsson Syndrome adult cohort; pediatric expansion submission expected H1 2024.
- Phase 2 trial of ADX-629 in moderate alcoholic hepatitis initiated; top-line results expected H2 2024.
- IND for ADX-246 submitted for phase 1 in healthy volunteers; expected to expand to atopic dermatitis patients; top-line results H2 2024.
- IND for ADX-248 expected in 2024 for phase 1/2 in dry AMD with dark adaptation deficit.
- De-prioritized ADX-629 in chronic cough and idiopathic nephrotic syndrome; new preclinical RASP modulator program in metabolic disease initiated.

## SEC filing metadata
- accession: 0001157523-24-000014
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/0001157523-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/a53876982.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000014
- JSON: https://secwatch.observer/filing/0001157523-24-000014.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.